UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July 10~~September 7, 2018

OSIRIS THERAPEUTICS, INC.

(Exact ~~name~~Name of Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Maryland	001-32966	71-0881115
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction ofincorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)

7015 Albert Einstein Drive, Columbia, Maryland		21046
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (443) 545 - 1800

~~Check~~ Not the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):Applicable

o (Former ~~Written~~name ~~communications~~or ~~pursuant~~former toaddress, ~~Rule 425~~if ~~under~~changed ~~the~~since ~~Securities~~last ~~Act (17 CFR 230.425~~report)

o Check ~~Soliciting~~the ~~material~~appropriate ~~pursuant~~box tobelow ~~Rule~~if the Form ~~14a~~8-12K ~~under~~filing is intended to simultaneously satisfy the ~~Exchange~~filing ~~Act~~obligation ~~(17~~of ~~CFR~~the ~~240.14a-12)~~registrant under any of the following provisions:

o ☐ ~~Pre-commencement~~Written communications pursuant to Rule ~~14d-2(b)~~ 425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~14d-2(b~~425))

o ☐ ~~Pre-commencement~~Soliciting ~~communications~~material pursuant to Rule ~~13e~~14a-~~4(c)~~ 12 under the Exchange Act (17 CFR 240.~~13e~~14d-42(cb))

~~Indicate~~ ☐ byPre-commencement ~~check~~communications ~~mark~~pursuant ~~whether~~to ~~the registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933~~ 14d-2(~~§230.405 of this chapter~~b) ~~or Rule~~ ~~12b-2~~under of the ~~Securities~~ Exchange Act of(17 ~~1934~~CFR (§240.~~12b~~14d-2 ~~of this chapter~~(b).)

~~Emerging~~ ☐ ~~growth~~Pre-commencement ~~company~~communications opursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

If Indicate ~~an emerging growth company, indicate~~ by check mark ifwhether the ~~registrant~~Registrant ~~has~~is ~~elected~~an ~~not~~emerging togrowth ~~use~~company ~~the~~as ~~extended~~defined ~~transition~~in ~~period~~Rule ~~for~~405 ~~complying~~of ~~with~~the ~~any~~Securities ~~new~~Act orof ~~revised~~1933 ~~financial~~(§230.405 ~~accounting~~of ~~standards~~this ~~provided~~chapter) ~~pursuant~~or toRule ~~Section 13(a)~~ 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 oof this chapter).

~~Item~~ Emerging ~~5.02~~growth ~~Departure~~company ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~☐

~~Joel~~ If ~~Rogers~~an ~~was~~emerging ~~appointed~~growth tocompany, ~~serve~~indicate asby ~~the~~check ~~Chief~~mark ~~Financial~~if ~~Officer of Osiris Therapeutics, Inc. (~~the ~~“Company”),~~Registrant ~~effective~~has aselected ofnot ~~July 10,~~to ~~2018.~~use ~~Mr. Rogers previously served as~~ the ~~Company’s~~extended ~~Interim~~transition ~~Chief~~period ~~Financial~~for ~~Officer~~complying ~~since~~with ~~May 9,~~any ~~2018.~~new ~~Mr. Rogers~~or ~~will~~revised ~~not~~financial ~~receive~~accounting ~~any~~standards ~~additional~~provided ~~compensation~~pursuant asto Section 13(a) ~~result~~ of ~~his~~the ~~appointment~~Exchange ~~as Chief Financial Officer~~Act. ☐

2 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~SIGNATURES~~ Departure of Directors

~~Pursuant~~ Effective toSeptember ~~the~~7, ~~requirements~~2018, ofDavid ~~the~~L. ~~Securities~~White, ~~Exchange~~and ~~Act~~effective September 11, 2018, Uwe Sommer, each resigned as a Director of ~~1934~~Osiris Therapeutics, Inc. (the ~~registrant~~“Company”). Neither ~~has~~Mr. White’s ~~duly~~nor Mr. Sommer’s resignation was caused ~~this~~by ~~report~~any todisagreement bewith ~~signed~~the Company on ~~its~~any ~~behalf~~matter byrelating to the ~~undersigned~~Company’s ~~hereunto~~operations, ~~duly~~policies ~~authorized~~or practices. Mr. Sommer resigned to pursue a business opportunity in the consumer goods industry that does not permit him to continue his Board activities with the Company.

	OSIRIS THERAPEUTICS, INC.
	By:	/s/ Jason Keefer
		Jason Keefer
		Interim President and Chief Executive Officer
Date: July 10, 2018

Appointment of Director

3 On September 11, 2018, the Board of Directors of the Company (the” Board”), upon recommendation of its Nominating Committee, appointed Mr. Charles A. Reinhart, C.P.A, M.B.A., as a Director. Mr. Reinhart will serve as the Chairperson for the Company’s Audit Committee.

Mr. Reinhart is currently the Chief Financial Officer of Pacira Pharmaceuticals, Inc. Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc., Archimedes Pharma Ltd. and PharmAthene, Inc. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. Mr. Reinhart has 30 plus years of experience building and managing finance and accounting organizations, raising capital, managing risks and implementing corporate development initiatives.

Mr. Reinhart will be entitled to receive the compensation received by Board members under the Company’s standard compensation policy and practices, which are described under the caption “Corporate Governance and Board Matters - Compensation of Directors” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on May 11, 2018, as may be adjusted by the Board from time to time. Mr. Reinhart does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	OSIRIS THERAPEUTICS, INC.

Dated: September 11, 2018	By:	/s/ JASON KEEFER
		Jason Keefer
		Interim President and Chief Executive Officer

Filing Compare · OSIRIS THERAPEUTICS, INC.